Selinexor FDA approval date

The FDA approved Selinexor (KPT-330) on 3 Jul 2019.

FDA approval date
3 Jul 2019

Drug identity checked against registry records

Also recorded as KPT-330; XPOVIO; XPOVIO®; Xpovio

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389KPTIPhase 3Active not recruiting2026-02-20Actual
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870KPTIPhase 2Active not recruiting2026-09Estimated
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562KPTIPhase 3Completed2020-02-18Actual
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434KPTIPhase 2Terminated2022-06-24Actual
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931KPTIPhase 3Active not recruiting2026-05-22Actual
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.NCT04414475KPTIPhase 2Recruiting2028-01Estimated
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaNCT04768881KPTIPhase 2Terminated2023-09-22Actual
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251KPTIPhase 2Terminated2026-06-02Actual
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422KPTIPhase 3Completed2022-01-22Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2019-07-03DaySelinexorFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA212306", "applicant_as_listed_by_fda": "KARYOPHARM THERAPS", "brand_names": ["XPOVIO"], "active_ingredients": ["SELINEXOR"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190703", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026